By Sabela Ojea
Shares of United Therapeutics fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations.
The stock was down 10%, to $321.90, in Wednesday trading. Shares are down 8.8% year to date, and have fallen 42% over the past 12 months.
The biotechnology company posted a net profit of $301.3 million, or $6.19 a share, compared with $217.1 million, or $4.36 a share, for the same period a year earlier. Analysts surveyed by FactSet had expected earnings of $6.40 a share.
Revenue rose 20%, to $735.9 million, offset by a 2.1% decline in Adcirca sales. Wall Street had expected revenue of $734.7 million, according to FactSet.
Adcirca is used to treat pulmonary arterial hypertension.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
February 26, 2025 12:08 ET (17:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。